JPM: More “Smaller, Smarter” M&A Deals Expected in 2025, EY Predicts
EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived 51% during 2024, to 92 from 186 the previous year.
Related Articles
JPM: More “Smaller, Smarter” M&A Deals Expected in 2025, EY Predicts
EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived 51% during 2024, to 92 from 186…
To Reverse Aging’s Clock, Adjust the Cell’s Machinery
Epigenetic, bioelectromic, synaptic, and senolytic interventions could rejuvenate cells and counter the effects of aging.
Inha University Hospital eyes Stage 7 EMRAM
The hospital east of South Korea’s capital Seoul largely serves international patients who require global quality care. CEO Tack Lee discusses.
J&J to Acquire Intra-Cellular for $14.6B
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.
Why the ‘Ferrari of viruses’ is surging through the Northern Hemisphere
Norovirus, which causes explosive diarrhea and vomiting, may be on the rise because of an antibody-dodging variant and post–COVID-19 socializing
Virtual Medicine Conference (vMed) 2025
Join us at Cedars-Sinai’s vMed conference, where experts will gather to explore the science of medical extended reality (VR/AR/MXR).
Supreme Court to hear ACA preventive coverage suit
The U.S. Supreme Court has agreed to hear a lawsuit that will determine whether preventive services will remain fully covered by group health plans under…
New Study Shows AliveCor’s Kardia 12L ECG System Performs Equivalently to a Standard 12-Lead ECG
/PRNewswire/ — AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced new data published in Computing in…
Timberlyne Therapeutics Launched Last Week with a $180 Million Series A Financing
Timberlyne Therapeutics launched last week with a $180 million Series A financing to advance CM313.
Sleep like a bear
Reduced expression of a platelet protein protects against thrombosis during chronic immobilization
